Home › Kidney Cancer › Pennsylvania › Pittsburgh
Kidney Cancer clinical trials in Pittsburgh, PA
5 studies for Kidney Cancer are looking for participants at sites in and around Pittsburgh (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
RecruitingPhase 1
- Research Site, Pittsburgh
Distance-Based Exercise to Preserve Function and Prevent Disability
Recruiting
- UPMC Hillman Cancer Center, Pittsburgh
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
RecruitingPhase 3
- Research Site, Monroeville · 11 mi away
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
RecruitingPhase 1
- UPMC Hillman Cancer Center, Pittsburgh
A Study of VET3-TGI in Patients With Solid Tumors
RecruitingPhase 1
- UPMC- Hillman Cancer Center, Pittsburgh
About Kidney Cancer
Kidney cancer symptoms are hard to detect at first but they do exist. Read more about the top 5 symptoms and the treatment options available
More about Kidney Cancer on MedlinePlus
Kidney Cancer trials in other cities
- New York City, NY15 studies
- Nashville, TN12 studies
- Boston, MA12 studies
- Houston, TX10 studies
- San Diego, CA9 studies
- St. Louis, MO9 studies
- Dallas, TX9 studies
- Washington, DC9 studies
- Seattle, WA8 studies
- Edison, NJ8 studies
- Miami, FL8 studies
- Los Angeles, CA7 studies
Other studies in Pittsburgh
- Non-Small Cell Lung Cancer48 studies
- Cancer (all types)41 studies
- Breast Cancer39 studies
- Colorectal Cancer32 studies
- Metastatic Cancer31 studies
- Melanoma31 studies
- Ovarian Cancer30 studies
- Endometrial Cancer23 studies
- Prostate Cancer23 studies
- Lung Cancer23 studies
- Head and Neck Squamous Cell Carcinoma22 studies
- Stroke22 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.